Tel:
Fax:
Email:
Creative Biolabs

NeuroMab™ Anti-EPHA2 BBB Shuttle Antibody(NRZP-1022-ZP3853)

[CAT#: NRZP-1022-ZP3853]

Host Species:
Mouse
Species Reactivity:
Human
Applications:
WB; In Vitro; In Vivo; Inhib

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

SPECIFIC INQUIRY

inquiry
Size:
Conjugation:
Endotoxin:
Purity:
Engineering:
Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Applications

WB; In Vitro; In Vivo; Inhib

Relevant Diseases

Glioblastoma Multiforme
Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only
Target

Target

EPHA2

Official Name

EPHA2

Full Name

EPH receptor A2 (ephrin type-A receptor 2)

Alternative Names

EPHA2; Epha2; AW545284; Eck; Myk2; Sek-2; Sek2; ARCC2; CTPA; CTPP1; CTRCT6; EPH receptor A2; ECK
Product Pictures
WB

Figure 1 EphA2 Eph099B-233.152 antibody promotes EphA2 tyrosine phosphorylation and EphA2 degradation in MDA-MB-231 cells.

MDA-MB-231 cell monolayers were incubated at 37°C in the presence of a single dose of 5 μg/ml Eph099B-233.152. Cell lysates were then immunoprecipitated with D7 (an EphA2-specific antibody), resolved by SDS-PAGE and subjected to western blot analysis with (A) phosphotyrosine-specific antibody or (B) EphA2-specific antibody.

FuncS

Figure 2A EphA2 Eph099B-233.152 antibody inhibits tumor cell growth in vivo.

Tumor growth. Tumor growth was assessed and expressed as the ratio of tumor volume divided by initial tumor volume (100 mm3). Control mice are indicated by circles and Eph099B-233.152-treated mice are indicated by squares. Arrows indicate the time of Eph099B-233.152 or PBS administration.

FuncS

Figure 2B EphA2 Eph099B-233.152 antibody inhibits tumor cell growth in vivo.

Survive. Tumors were allowed to grow until the tumor volume reached 1000 mm 3 . Mice survival was assessed by scoring the percentage of mice surviving each day after treatment. Control mice are shown in gray and Eph099B-233.152-treated mice are shown in black.

FuncS

Figure 3 EphA2 antibodies EA2, Eph099B-208.261 and Eph099B-233.152 inhibit tumor cell growth in vivo.

MDA-MB-231 breast cancer cells were implanted (A) orthotopically or (B) subcutaneously into athymic mice. (C) A549 lung cancer cells were implanted subcutaneously in athymic mice. After tumor growth to an average volume of 100 mm3, mice were administered 6 mg/kg of the indicated antibody or negative control (PBS or 1A7 antibody) intraperitoneally twice weekly for 3 weeks. Tumor growth was assessed and expressed as the ratio of tumor volume divided by initial tumor volume (100 mm3).

FuncS

Figure 4 EphA2 antibodies EA2, Eph099B-208.261 and Eph099B-233.152 inhibit tumor cell growth in vivo.

MDA-MB-231 breast cancer cells were implanted subcutaneously in athymic mice. After tumor growth to an average volume of 100mm3, mice were dosed intraperitoneally with 6 mg/kg of the indicated antibody or negative control twice a week for 3 weeks. Total tumor volume was determined after sacrifice. The negative control is black, EA2 is white, Eph099B-208.261 is dark gray, and Eph099B-233.152 is light gray.

FuncS

Figure 5 Kinetic analysis of EphA2 monoclonal antibodies.

The BIACORE™ (surface plasmon resonance-based) assay was used to determine the kinetics of binding of EphA2 mAb to immobilized EphA2-Fc. Eph099B-208.261 is represented by a solid line, Eph099B-233.152 is represented by a dotted line, EA2 is represented by a dotted line, and the negative control is represented by squares.

FuncS

Figure 6A The EphA2 EA2 epitope is distinct from the Eph099B-233.152 epitope and ligand binding site.

(A) EphA2-Fc was incubated with and bound to immobilized ephrin A1-Fc. Labeled ephrin A1-Fc (black), EA2 (white) or Eph099B-233.152 (grey) was incubated with EphA2-ephrin A1-Fc complex and the amount of binding measured.

FuncS

Figure 6B The EphA2 EA2 epitope is distinct from the Eph099B-233.152 epitope and ligand binding site.

(B) EphA2-Fc incubated with and bound to immobilized Ephrin A1-Fc. Labeled EA2 was then incubated with the EphA2-Ephrin A1 complex. Unlabeled competitors were incubated with the indicated amounts of EphA2-Ephrin A1-EA2 complexes. Competitors are Ephrin A1-Fc (black), EA2 (white) or Eph099B-233.152 (gray).

Publications

Publications (0)

gift-card

Related Products
For Research Use Only. Not For Clinical Use.
Product
Hot Products
Fill out this form for a quote Inquiry Form Send Inquiry
webinar

The Spectrum of Stem Cell-Based Neuronal Models and Their Fit for Purpose

2:00 PM–3:00 PM EST, December 12, 2024

REGISTER NOW
Inquiry Basket
compare

Send inquiry